Technology transfer / Localization · MENA · Announced 3 Nov 2026
Geropharm → Al Quds Medical Products
Al Quds Medical Products Group signed a strategic partnership with biologics maker Geropharm to license, market and manufacture endocrine and metabolic biologics in Saudi Arabia, the UAE and Jordan, with technology transfer to two regional plants.
Parties: Geropharm (Russia) → Al Quds Medical Products Group (Jordan)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia, United Arab Emirates and Jordan; technology transfer to Nahr Al Urdon Pharmaceuticals (Jordan) and Aman Pharma (Saudi Arabia)
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Biologics portfolio – endocrinology and metabolic health (molecules not named)
- Announced
- 3 Nov 2026
Our analysis
Why this matters
Al Quds Medical Products Group has signed a strategic partnership with Geropharm, a biotechnology company that develops and manufactures biologic drugs for endocrinology and metabolic health. Under the agreement, Al Quds will handle licensing, marketing and manufacturing of Geropharm biologics in Saudi Arabia, the UAE and Jordan, with technology transfer to two sites: Nahr Al Urdon Pharmaceuticals in Jordan and Aman Pharma in Saudi Arabia. No products or financial terms were disclosed.
Al Quds operates manufacturing and commercial entities in Palestine, Jordan and Algeria and has platforms in Saudi Arabia and the UAE. The partnership is presented as a move from generics into higher-value biologics.
The full analysis is free to read with a work email on this page.
Source: Souq Al Dawaa Saudi